Introduction
============

Thiopurines, such as 6-mercaptopurine (6-MP) are widely used for the treatment of childhood acute lymphoblastic leukemia (ALL). The optimized use of 6-MP has shown a remarkable improvement in survival \[[@b1-crt-2017-283],[@b2-crt-2017-283]\]. As per treatment protocols, children with ALL are exposed to thiopurines on a daily basis for up to two or three years during maintenance therapy \[[@b3-crt-2017-283],[@b4-crt-2017-283]\].

Hematopoietic toxicity is one of the most important dose-limiting adverse effects of thiopurines \[[@b5-crt-2017-283],[@b6-crt-2017-283]\]. East Asians are the ethnic group most affected by thiopurines \[[@b7-crt-2017-283],[@b8-crt-2017-283]\]. Patients often experience serious bone marrow suppression, infectious complications, and interruptions in therapy. Low systemic exposure to thiopurines affects prognosis \[[@b9-crt-2017-283],[@b10-crt-2017-283]\]. Lower 6-MP dose intensity is primarily due to a missed period of therapy, not reductions in the daily dose \[[@b10-crt-2017-283]\]. In a Children's Oncology Group (COG) study, 6-MP non-adherence and high intra-individual variability in thiopurine metabolites were associated with relapse risk \[[@b11-crt-2017-283]\]. Thiopurine S-methyltransferase (*TPMT*) variants are well-established genetic determinants for cytotoxicity of thiopurines \[[@b12-crt-2017-283],[@b13-crt-2017-283]\]. Dose adjustment guidelines based on 6-thioguanine nucleotide (6-TGN) levels have enabled patients with *TPMT* variants to minimize hematopoietic toxicity while maintaining its therapeutic effect \[[@b14-crt-2017-283],[@b15-crt-2017-283]\].

Nucleoside diphosphate--linked moiety X-type motif 15 (*NUDT15*) has recently been discovered to be associated with hematopoietic toxicity, initially in patients with inflammatory bowel disease \[[@b16-crt-2017-283]\]. A negative effect of *NUDT15* variants was also revealed in children with ALL by previous reports that mainly focused on the less tolerated doses of 6-MP in patients with *NUDT15* variants \[[@b17-crt-2017-283]-[@b19-crt-2017-283]\]. The hypothesis about the mechanism of *NUDT15* variants suggested that the NUDT15 protein encoded by *NUDT15* might prevent 6-TGN, the active metabolite of thiopurine, from being incorporated into the DNA \[[@b20-crt-2017-283]\]. This hypothesis has been supported by Moriyama et al. \[[@b18-crt-2017-283]\], who recently reported a high thioguanosine triphosphate (TGTP)/monophosphate thioguanosine nucleotide (TGMP) ratio in a *NUDT15* knockdown cell line, and high DNA-incorporated thioguanine (DNA-TG) levels in children with ALL with *NUDT15* variants. Contrary to TPMT variants, there is poor information about thiopurine dose alteration for patients with *NUDT15* variants. Considering the proposed hypothesis about the NUDT15 protein, *NUDT15* variants are assumed to cause cytotoxicity independent of the 6-TGN levels; therefore, the same guidelines that apply to *TPMT* variants would not be applicable to patients with *NUDT15* variants. This study aimed to analyze the levels of 6-TGN, which is widely used in clinics, according to *NUDT15* variants.

In addition, this study intended to analyze hematopoietic toxicity based on *NUDT15* diplotypes in Korean children with ALL more comprehensively. All six discovered haplotypes were screened. We collected clinical and laboratory information of patients during their first year of maintenance therapy because previous reports seemed to use limited indices for measuring hematopoietic toxicity or thiopurine intolerance \[[@b17-crt-2017-283],[@b18-crt-2017-283]\].

Materials and Methods
=====================

1. Study patients and *NUDT15* genotyping
-----------------------------------------

*NUDT15* genotyping was retrospectively conducted in 258 children with ALL who underwent *TPMT* genotyping at Samsung Medical Center in Korea for research purposes from 2004 to 2015 (IRB file No. SMC 2012-04-106-014). Genomic DNA was extracted from whole blood using Wizard genomic DNA purification kit according to the manufacturer's instructions (Promega, Madison, WI) \[[@b21-crt-2017-283]\]. Exons 1 and 3, and their intron-exon boundaries of *NUDT15* were amplified by polymerase chain reaction (PCR) using primers designed by our institute. For exon 3, PCR was performed using a GeneAmp PCR system 9700 thermal cycler (Biometra, Applied Biosystems Life Technologies, Foster City, CA) with 35 cycles at 94°C for 20 seconds, 60°C for 30 seconds, and 72°C for 40 seconds. An Eppendorf pro S (Eppendorf) was used for exon 1 with 50 cycles at 95°C for 20 seconds, 62°C for 30 seconds, and 72°C for 40 seconds. Five microliters of the amplicon for both exons was treated with 10 U exonuclease I (USB Corp., Cleveland, OH) at 37°C for 15 minutes, and then incubated at 80°C for 15 minutes to inactivate the enzyme. Cycle sequencing was performed using Big Dye Terminator Cycle Sequencing Ready Reaction kits (Applied Biosystems) in an ABI 3130xl Genetic Analyzer (Applied Biosystems). Direct sequencing of exons 1 and 3 of *NUDT15* (NCBI reference sequence NM_018283.3) was performed.

Based on previous reports that demonstrated a decreased *NUDT15* activity and an increased risk of hematopoietic toxicity with a number of variant alleles \[[@b18-crt-2017-283]\], study patients were classified into three groups according to their *NUDT15* diplotype: normal-activity group (wild-type), intermediate-activity group (heterozygous variant), or low-activity group (homozygous or compound heterozygous variant). Patient demographics at diagnosis and clinical features and laboratory results during the first year of maintenance therapy were obtained from patients who had received maintenance therapy, including 6-MP at Samsung Medical Center via retrospective chart review. Patents with *TPMT* variants were excluded from the analysis.

2. 6-TGN assays
---------------

Since May 2009, thiopurine metabolites assay has been studied using whole blood from patients initially at 14th day after beginning maintenance therapy and at 14th day after dose alteration, until the white blood cell (WBC) count and 6-TGN levels were within the target range. It was performed only when patients had taken the same dose of 6-MP for at least 14 days. Red blood cell (RBC) levels of 6-TGN were measured using a liquid chromatography--tandem mass spectrometry method \[[@b22-crt-2017-283]\]. Metabolite levels were normalized to an RBC count of 8×10^8^. The limit of quantification was 0.1 μmol/L for 6-TGN, corresponding to quantification limits of approximately 10 pmol per 8×10^8^ RBC for 6-TGN \[[@b23-crt-2017-283]\].

3. ALL risk stratification and treatment schedule
-------------------------------------------------

Patients ≥ 10 years or \< 12 months of age, or who had an initial WBC count ≥ 50×10^9^/L were considered as high-risk patients at initial diagnosis. All others were considered as standard-risk patients. Patients with any high-risk characteristics received more intensified chemotherapy during induction and consolidation therapy compared to standard-risk patients. Patients with at least one of the characteristics, including an initial WBC count of ≥ 200×10^9^/L, positive bcr/abl rearrangement, hypodiploidy under 45 chromosomes by cytogenetics, t(4;11), or remission failure received allogeneic stem cell transplantation when a suitable donor was available.

Maintenance therapy consisted of daily oral 6-MP (50 mg/m^2^), weekly oral methotrexate (15 mg/m^2^), oral prednisolone (40 mg/m^2^) for 5 days, intravenous vincristine (1.5 mg/m^2^) every 4 weeks, and intrathecal triple therapy (methotrexate, cytarabine, and hydrocortisone) every 12 weeks. 6-MP and methotrexate doses were altered at the discretion of pediatric oncologists based on the complete blood count (CBC) and 6-TGN levels. When the WBC count was consecutively out of target range (1.5-3.0×10^9^/L), the 6-MP dose was adjusted if 6-TGN levels were out of therapeutic range (235-450 pmol/8×10^8^ RBC), or the methotrexate dose was altered if 6-TGN levels were within the therapeutic range. Treatment was interrupted if patients developed significant hematopoietic toxicity (absolute neutrophil count \< 0.5×10^9^/L or platelet count \< 50×10^9^/L) or a serious infectious event.

4. Statistical analysis
-----------------------

Clinical features and laboratory results at initial diagnosis and during the first year of maintenance therapy were compared across groups using chi-square and Fisher exact tests for categorical variables, and one way analysis of variance (ANOVA) or Kruskal-Wallis test along with Tukey test using ranks for continuous variables. Because 6-MP doses were frequently altered during the initial period of maintenance therapy, 6-MP doses during the initial 3 months were excluded from analysis for comparing the administered 6-MP doses between the groups. Consequently, 6-MP doses from 3 months to a year after maintenance therapy were compared. Correlation between the 6-TGN level and 6-MP dose was analyzed by Pearson's correlation analysis. Subsequently, the ratio of 6-TGN level to 6-MP dose was compared among the groups. All statistical analyses were performed using SPSS ver. 22.0 (IBM Corp., Armonk, NY).

5. Ethical statement
--------------------

The study was approved by the Institutional Review Board of Samsung Medical center (IRB No. SMC 2017-01-015-001) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived.

Results
=======

1. Characteristics of study patients
------------------------------------

*NUDT15* genotyping was conducted for a total of 258 patients ([Fig. 1](#f1-crt-2017-283){ref-type="fig"}). According to their *NUDT15* diplotype, 190 patients were wild-type (73.6%), 61 patients had a single variant allele (23.6%), and seven patients had variants on both alleles (2.7%). Allele frequency and composition of *NUDT15* diplotypes in the study population are described in [Tables 1](#t1-crt-2017-283){ref-type="table"} and [2](#t2-crt-2017-283){ref-type="table"}, respectively. Regarding allele frequency, *NUDT15*\*1 (wild-type) was the most common (85.5%), followed by \*3 (7.9%) and \*2 (5.2%). Regarding diplotype frequency, *NUDT15*\*1/\*3 (12.8%) was the most common variant, followed by *NUDT15*\*1/\*2 (8.5%). All six previously known haplotypes were observed in this study.

Of the total study population, 76 patients were excluded from the analysis. Forty-three patients stopped maintenance therapy for hematopoietic stem cell transplantation (n=37) or due to death during induction or consolidation therapy (n=6). Sixteen patients received maintenance therapy at other hospitals. Ten patients received maintenance therapy without daily 6-MP, according to adult ALL treatment protocols (n=5) or other protocols (n=5). Seven patients were *TPMT* heterozygous. A total of 182 patients were included in the final analysis. To analyze hematopoietic toxicity based on *NUDT15* diplotypes, patients were classified into three groups: normal-activity (n=131), intermediate-activity (n=46), and low-activity (n=5) groups. Characteristics of the study patients are summarized in [Table 3](#t3-crt-2017-283){ref-type="table"}. The three groups were similar with respect to demographic characteristics, including sex, age, ALL risk group, initial WBC counts, cytogenetic results, immunophenotype, and rapid early response, except central nervous system disease at diagnosis.

2. Hematopoietic toxicity according to *NUDT15* diplotypes
----------------------------------------------------------

[Fig. 2](#f2-crt-2017-283){ref-type="fig"} shows the daily 6-MP doses administered to patients, duration of therapy interruption, and proportion of patients who experienced febrile neutropenia. Daily 6-MP dose was defined as the average daily dose of 6-MP administered from three months to a year after maintenance therapy. The 6-MP dose during therapy interruption was considered to be zero. With accretion of risk by *NUDT15* diplotype, the daily 6-MP doses were decreased and therapy interruption days were increased. Mean daily 6-MP doses (±standard deviation \[SD\]) were 31.1±8.7 mg/m^2^ in the normal-activity group, 24.4±7.7 mg/m^2^ in the intermediate-activity group, and 7.5±3.0 mg/m^2^ in the low-activity group (p \< 0.01). The mean number of interrupted days in the first year of maintenance therapy (±SD) were 15.5±17.8, 30.3±29.4, and 168.8±50.1 days in the normal-, intermediate-, and low-activity groups, respectively (p \< 0.01). Febrile neutropenia was most frequent in the low-activity group during the first year of maintenance therapy (normal-activity group 14.6% vs. intermediate-activity group 15.2% vs. low-activity group 80%, p \< 0.01).

The lowest values of CBC, including WBC, neutrophil, platelet, and hemoglobin are shown in [Fig. 3](#f3-crt-2017-283){ref-type="fig"}. The low-activity group had the lowest levels of all the blood cell lineages. The means of the lowest WBC counts (±SD) were (1.358±0.575)×10^9^/L in the normal-activity group, (1.114±0.295)×10^9^/L in the intermediate-activity group, and (0.620±0.254)×10^9^/L in the low-activity group (p \< 0.01). The mean of the lowest absolute neutrophil count (±SD) was lowest in the low-activity group (\[0.040±0.037\]×10^9^/L) compared to that in the normal-activity group (\[0.434±0.405\]×10^9^/L) or the intermediateactivity group (\[0.293±0.196\]×10^9^/L). The means of the lowest hemoglobin levels (±SD) were 10.1±1.1 g/dL in the normal-activity group, 9.8±1.1 g/dL in the intermediate-activity group, and 7.4±1.0 g/dL in the low-activity group (p \< 0.01). The means of the lowest platelet counts in the low-activity group (±SD) were extremely low (\[9±5\]×10^9^/L) compared to those in the normal-activity group (\[137±53\]×10^9^/L) or the intermediate-activity group (\[115±43\]×10^9^/L). The duration of leukopenia, defined as WBC \< 2×10^9^/L, increased with increasing risk of *NUDT15* diplotype ([Fig. 4](#f4-crt-2017-283){ref-type="fig"}). The low-activity group experienced the most number of days of leukopenia (mean±SD, 131±68 days), followed by those in the intermediate-activity group (92±46 days) and the normal-activity group (59±45 days).

3. 6-TGN level and its ratio to 6-MP dose according to *NUDT15* diplotype
-------------------------------------------------------------------------

A total of 671 results of 6-TGN levels were obtained from 117 of the 182 patients (26 results from 5 patients in the low-activity group, 173 from 24 patients in the intermediateactivity group, and 472 from 88 patients in the normal-activity group). [Fig. 5](#f5-crt-2017-283){ref-type="fig"} shows the 6-TGN levels of patients whose 6-MP dose was stable for at least 14 days. The median 6-TGN levels (range) were 383 (135-1,461) pmol/8×10^8^ RBC in the normal-activity group, 286 (94-1,145) pmol/8×10^8^ RBC in the intermediate-activity group, and 78 (5-171) pmol/8×10^8^ RBC in the low-activity group (p \< 0.01). A positive correlation was seen for 6-TGN levels in the whole study population (coefficient of correlation, 0.30; p \< 0.01). To assess the 6-TGN levels with equal doses of 6-MP, the ratio of 6-TGN level to 6-MP dose was compared across groups ([Fig. 6](#f6-crt-2017-283){ref-type="fig"}). Patients in the low-activity group had the lowest ratio (mean±SD, 4.4±2.7) as compared to those in the intermediate-activity group (13.3±7.5) and the normal-activity group (14.7±9.1).

The 6-TGN levels in the low-activity group were below the alleged level associated with a higher risk of leukopenia (450 pmol/8×10^8^ RBC) \[[@b22-crt-2017-283]\]. In 26 results from the low-activity group, 10 (38.5%) were performed while the patient had grade ≥ 3 leukopenia or thrombocytopenia (platelets \< 50×10^9^/L).

Discussion
==========

More than a quarter of the Korean children in this study had *NUDT15* variants. A lower dose of 6-MP was administered to them. They experienced therapy interruption and febrile neutropenia more frequently. They also experienced more severe cytopenia in all types of peripheral blood cells and the duration of leukopenia was longer. A lower 6-TGN level and a lower 6-TGN/6-MP ratio were also observed.

The lower ratio of 6-TGN level to 6-MP dose in patients with *NUDT15* variants is opposite to that in patients with *TPMT* variants \[[@b24-crt-2017-283]\]. The mechanism of cytotoxicity in *TPMT* variants is known to be related to increased 6-TGN levels because TPMT encoded by *TPMT* controls the anabolic transformation of thiopurine metabolites to active metabolites and regulates the cytotoxic effect of thiopurines in children with ALL \[[@b25-crt-2017-283]\]. By phosphorylation, thiopurines are converted to TGMP, TGDP, and TGTP, and then further reduced to TdGMP, TdGDP, and TdGTP. TdGTP is directly incorporated into DNA and eventually triggers apoptosis \[[@b5-crt-2017-283]\]. It has been suggested that *NUDT15* may prevent incorporation of 6-TGN into DNA via dephosphorylation of 6-TGN metabolites in the thiopurine metabolism pathway \[[@b18-crt-2017-283],[@b20-crt-2017-283],[@b26-crt-2017-283]\]. Therefore, loss-of-function *NUDT15* variants confer susceptibility to thiopurine-induced cytotoxicity \[[@b16-crt-2017-283]\]. With the high DNA-TG level in patients with *NUDT15* variants shown by Moriyama et al. \[[@b18-crt-2017-283]\], a low ratio of 6-TGN level to 6-MP dose in the low-activity group in our study seemed to be concordant with the existing hypothesis because active thiopurine metabolites could be incorporated into DNA by a defective protective mechanism resulting from loss-of-function *NUDT15* variants.

Erythrocyte 6-TGN concentrations \< 235 pmol/8×10^8^ RBC are considered to be associated with a greater likelihood of treatment failure, whereas 6-TGN concentrations \> 450 pmol/8×10^8^ RBC are associated with a higher risk of leukopenia \[[@b22-crt-2017-283]\]. Interestingly, 6-TGN levels were far below 450 pmol/8×10^8^ in all patients in the low-activity group, the maximum 6-TGN level being 171 pmol/8×10^8^ RBC. At the same time, the low-activity group showed highest hematopoietic toxicity. Ten of 26 6-TGN results in the low-activity group were performed while patients had grade 3/4 leukopenia or thrombocytopenia. These findings in the low-activity group imply the possibility that bone marrow suppression can result even from low levels of 6-TGN in patients with *NUDT15* variants. Hematopoietic toxicity could not be anticipated by 6-TGN level alone in patients with *NUDT15* variants, and therefore, existing 6-MP dose guidelines for *TPMT* variants are not applicable to this population. Although DNA-TG may seem more appropriate because it is the final metabolite of 6-MP therapy and has been recently reported to be correlated with TGN, 6-TGN levels have been more extensively studied and widely used in the clinical setting to monitor dose escalation or de-escalation in patients receiving 6-MP therapy \[[@b27-crt-2017-283]\]. Additionally, DNA-TG still requires prospective validation \[[@b28-crt-2017-283]\]. The development of clinically available monitoring methods is required for patients with *NUDT15* variants. The effort to improve clinical validation of DNA-TG could be useful.

Few studies have analyzed 6-TGN levels using whole blood from patients with ALL according to their *NUDT15* diplotypes. A Japanese group briefly reported that TGN levels were lower in patients with *NUDT15* variants \[[@b29-crt-2017-283]\]. However, our study was performed on a much larger scale. A total of 182 children were included in our study, compared to 55 children reported in their study. In addition, while they analyzed two TGN results from a patient with high-risk, 26 results from five patients in the low-activity group were analyzed in this study.

In our study, patients with *NUDT15* variants frequently experienced more serious bone marrow suppression and febrile neutropenia after administration of 6-MP, and showed serious 6-MP intolerance. The adverse effects and 6-MP intolerance got more severe as the number of variant alleles increased. Several previous reports have demonstrated thiopurine intolerance in patients with ALL with *NUDT15* variants. Patients with *NUDT15* variants in both alleles have been reported to use an extremely low dose of 6-MP, consistent with our results \[[@b17-crt-2017-283],[@b18-crt-2017-283]\]. Clinical and laboratory information in this study were comprehensively collected during a year of maintenance therapy, which is a relatively longer study duration compared to other reports. Moriyama et al. \[[@b18-crt-2017-283]\] used the tolerated MP dose to compare thiopurine intolerance between groups according to *NUDT15* diplotype. Tolerated MP dose was defined as the average of at least 14 daily doses after at least nine weeks of maintenance therapy. Another study defined MP dose intensity as the ratio between clinically prescribed MP dose and protocol dose, and it was monitored on a monthly basis for the entire six-month duration of the study \[[@b17-crt-2017-283]\]. Since previous studies did not provide complete information on thiopurine intolerance, the daily dose of 6-MP administered during a period of 1 year was investigated in this study. All six alleged haplotypes from four coding variants were screened, which is distinct from many previous reports that investigated a single mutation of rs116855232, since other variants beyond rs116855232 have only been recently discovered \[[@b18-crt-2017-283]\].

There were some differences in clinical and laboratory results between the intermediate-activity and normal-activity groups. While the intermediate-activity group was administered a significantly lower daily 6-MP dose and experienced therapy interruption and leukopenia more frequently than the normal-activity group, the incidence of febrile neutropenia was not significantly different between these groups. Moreover, while the lowest WBC and platelet counts were significantly different between these two groups, the absolute neutrophil counts and hemoglobin levels were not significantly different between the two groups. Thus, it could be interpreted that patients with a wild-type *NUDT15* allele could maintain a somewhat protective effect but they were not capable of preventing thiopurine toxicity with doses over a certain range. Compared to WBC counts or hemoglobin levels, platelet counts were most significantly different between groups, which indicated that megakaryopoiesis is the more sensitive to thiopurine in patients with *NUDT15* variants.

Unlike *TPMT* variants, which are rare in Asian population, studies have shown that *NUDT15* variants were mostly discovered in this population, particularly in East Asians \[[@b16-crt-2017-283]-[@b18-crt-2017-283],[@b21-crt-2017-283],[@b30-crt-2017-283]\]. In this study, 26.4% of the patients had variant alleles. Additionally, the composition of diplotypes in this study was similar to that in 1000 Genomes Project and a recent Korean study \[[@b21-crt-2017-283]\]. rs116855232, which was the first reported *NUDT15* variant, was verified to be the most common variant. Patients with wild-type *NUDT15* were administered a mean daily 6-MP dose of 31.1 mg/m^2^/day, which was a substantially lower dose than the planned dose in the majority of ALL treatment protocols. A similar observation was made in other studies \[[@b31-crt-2017-283]\]. A previous study reported that East Asian genetic ancestry remained associated with 6-MP dose intensity after adjusting for rs116855232 \[[@b17-crt-2017-283]\], suggesting that there may be other undiscovered genetic or environmental factors affecting Asians. Kim et al. \[[@b32-crt-2017-283]\], recently reported that APEX1 rs2307486 variants conferred an increased risk of mercaptopurine-related early onset neutropenia in Korean pediatric ALL patients.

Even though this was a retrospective analysis, this study aimed to exclude possible compounding factors. Patients with *TPMT* variants were excluded from this study before analysis. 6-MP doses during the initial 3 months were excluded when comparing the 6-MP doses between the groups because 6-MP doses were frequently altered during the initial period. Demographic characteristics were not different between the groups. A limitation of this study was that it did not evaluate other anti-neoplastic agents used during maintenance therapy, such as methotrexate or vincristine.

It remains unclear whether *NUDT15* genotype affects survival in children with ALL. Even though this study did not analyze relapse or survival, irrelevance between them was suggested because survival rates were not significantly different according to *NUDT15* genotype in previous reports \[[@b11-crt-2017-283]\]. However, most of the earlier reports evaluated only a few patients with *NUDT15* variants \[[@b31-crt-2017-283]\]. A previous COG study about thiopurines and risk of relapse in children with ALL demonstrated that 6-MP non-adherence and high intraindividual variability in TGN levels contributes to increased relapse risk \[[@b11-crt-2017-283]\]. Since patients with *NUDT15* variants are exposed to frequent therapy interruptions, which can cause variability in TGN levels, *NUDT15* genotype should be screened before 6-MP administration. 6-MP dose should be carefully administered and altered in high-risk populations. Further extensive studies on the impact of *NUDT15* variants on treatment outcomes are required.

In conclusion, 6-TGN levels were substantially low in patients with *NUDT15* variants who showed highest hematopoietic toxicity. The low ratio of 6-TGN level to 6-MP dose in patients with *NUDT15* variants seems to be caused by enhanced incorporation of active thiopurine metabolites into DNA. With a known high incidence of *NUDT15* variants in East Asia, *NUDT15* genotype should be identified before thiopurine is administered. Thiopurine dose adjustment demands great caution in patients with *NUDT15* variants regardless of their 6-TGN levels. Further studies are required for validating thiopurine dose guidelines in this population.
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![Study population. Patients were classified into normal-, intermediate-, low-activity groups according to the number of variant alleles. 6-MP, 6-mercaptopurine; HCT, hematopoietic stem cell transplantation; *TPMT*, thiopurine S-methyltransferase.](crt-2017-283f1){#f1-crt-2017-283}

![Daily 6-mercaptopurine (6-MP) dose and clinical features of the groups. (A) Daily 6-MP dose. (B) Therapy interruption days. (C) Incidence of febrile neutropenia.](crt-2017-283f2){#f2-crt-2017-283}

![Lowest level of complete blood cell counts in the groups. (A) Lowest white blood cell (WBC) counts. (B) Lowest absolute neutrophil counts (ANCs). (C) Lowest hemoglobin (Hb) levels. (D) Lowest platelet (Plt) counts.](crt-2017-283f3){#f3-crt-2017-283}

![Duration of leukopenia in the various groups. WBC, white blood cell.](crt-2017-283f4){#f4-crt-2017-283}

![6-Thioguanine nucleotide (6-TGN) levels and 6-mercaptopurine (6-MP) doses of the study population. RBC, red blood cell.](crt-2017-283f5){#f5-crt-2017-283}

![Ratio of the 6-thioguanine nucleotide (6-TGN) level to 6-mercaptopurine (6-MP) dose between the groups.](crt-2017-283f6){#f6-crt-2017-283}

###### 

Allele frequency in the study population

  *NUDT15* allele   Genetic variant                   Protein variant                      Proportion (%)
  ----------------- --------------------------------- ------------------------------------ ----------------
  \*1               Wild-type                         Wild-type                            85.5
  \*2               c.\[36_37insGGAGTC; c.415C\>T\]   p.Val18_Val19insGlyVal/p.Arg139Cys   5.2
  \*3               c.415C\>T                         p.Arg139Cys                          7.9
  \*4               c.416G\>A                         p.Arg139His                          0.2
  \*5               c.52G\>A                          p.Val18Ile                           0.8
  \*6               c.36_37insGGAGTC                  p.Val18_Val19insGlyVal               0.4

###### 

Composition of *NUDT15* diplotypes in the study population

  Diplotype   No. of patients (n=258)   Proportion (%)
  ----------- ------------------------- ----------------
  \*1/\*1     190                       73.6
  \*1/\*2     22                        8.5
  \*1/\*3     33                        12.8
  \*1/\*5     4                         1.6
  \*1/\*6     2                         0.8
  \*2/\*3     4                         1.6
  \*2/\*4     1                         0.4
  \*3/\*3     2                         0.8

###### 

Characteristics of the study patients and composition of diplotypes

                                                                                All patients (n=182)   Normal-activity group (n=131)   Intermediate-activity group (n=46)   Low-activity group (n=5)   p-value
  ----------------------------------------------------------------------------- ---------------------- ------------------------------- ------------------------------------ -------------------------- ---------
  **Age (yr)**                                                                                                                                                                                         
   At diagnosis                                                                 5.2 (1.1-21.3)         5.2 (1.1-21.3)                  4.8 (1.1-16.0)                       6.1 (3.5-13.5)             0.53
   At maintenance                                                               6.0 (1.9-22.0)         6.0 (1.9-22.0)                  5.7 (2.0-17.2)                       7.1 (4.6-14.8)             0.52
  **Sex**                                                                                                                                                                                              
   Female                                                                       86 (47.3)              61 (46.6)                       21 (45.7)                            4 (80.0)                   0.33
   Male                                                                         96 (52.7)              70 (53.4)                       25 (54.3)                            1 (20.0)                   
  **ALL risk group**                                                                                                                                                                                   
   Standard                                                                     117 (64.3)             85 (64.9)                       30 (65.2)                            2 (40.0)                   0.52
   High                                                                         65 (35.7)              46 (35.1)                       16 (34.8)                            3 (60.0)                   
  **WBC counts at diagnosis (×10^9^/L)**                                                                                                                                                               
   \< 50                                                                        171 (94.0)             125 (95.4)                      41 (89.1)                            5 (100)                    0.604
   50-100                                                                       9 (4.9)                5 (3.8)                         4 (8.7)                              \-                         
   \> 100                                                                       2 (1.1)                1 (0.8)                         1 (2.2)                              \-                         
  **Favorable cytogenetics^[a)](#tfn1-crt-2017-283){ref-type="table-fn"}^**                                                                                                                            
   No                                                                           75 (41.4)              51 (39.2)                       23 (50.0)                            1 (20.0)                   0.273
   Yes                                                                          106 (58.6)             79 (60.8)                       23 (50.0)                            4 (80.0)                   
  **Unfavorable cytogenetics^[b)](#tfn2-crt-2017-283){ref-type="table-fn"}^**                                                                                                                          
   No                                                                           167 (92.3)             121 (93.1)                      41 (89.1)                            5 (100)                    0.556
   Yes                                                                          14 (7.7)               9 (6.9)                         5 (10.9)                             \-                         
  **CNS disease at diagnosis**                                                                                                                                                                         
   No                                                                           166 (92.2)             120 (93.0)                      43 (93.5)                            3 (60.0)                   0.28
   Yes                                                                          4 (2.2)                3 (2.3)                         \-                                   1 (20.0)                   
   Traumatic tap                                                                10 (5.6)               6 (4.7)                         3 (6.5)                              1 (20.0)                   
  **Immunophenotype**                                                                                                                                                                                  
   B                                                                            173 (95.1)             125 (95.4)                      43 (93.5)                            5 (100)                    0.969
   T                                                                            6 (3.3)                4 (3.1)                         2 (4.3)                              \-                         
   Others                                                                       3 (1.6)                2 (1.5)                         1 (2.2)                              \-                         
  **RER**                                                                                                                                                                                              
   No                                                                           66 (36.9)              44 (34.1)                       20 (44.4)                            2 (40.0)                   0.460
   Yes                                                                          113 (63.1)             85 (65.9)                       25 (55.6)                            3 (60.0)                   

Values are presented as median (range) or number of patients (%). Missing data for the following: favorable cytogenetics (n=1), unfavorable cytogenetics (n=1), CNS disease at diagnosis (n=2), and RER (n=3). ALL, acute lymphoblastic leukemia; WBC, white blood cell; CNS, central nervous system; RER, rapid early response.

Favorable cytogenetics included ≥ 1 of the following: t(12;21), hyperdiploidy, trisomy 4 and 10, or trisomy 4, 10, and 17,

Unfavorable cytogenetics included ≥ 1 of the following: t(9;22), t(4;11), iAMP21, or hypodiploidy.

[^1]: Eun Sang Yi and Young Bae Choi contributed equally to this work.
